Physician profile
Thomas E Meister
NPI 1689761371
$17,432.36
in general payments reported to CMS, 2019-2025
41 companies · $2,975 in 2025
The $2,975 reported for 2025 was more than what 87% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,162 · 2020: $1,594 · 2021: $2,531 · 2022: $2,355 · 2023: $2,508 · 2024: $3,307 · 2025: $2,975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,790.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,236.30 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,439.64 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $1,734.70 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $1,389.51 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Gilead Sciences, INC. | $1,302.65 | 2019-2025 | Livdelzi |
| Qol Medical, LLC | $713.38 | 2019-2025 | Sucraid, Sucraid |
| Pfizer INC. | $605.77 | 2019-2025 | |
| Celgene Corporation | $548.86 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $431.23 | 2023-2025 | Omvoh |
| Genzyme Corporation | $430.13 | 2022-2025 | |
| Ardelyx, INC. | $388.10 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $364.49 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $354.36 | 2019-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $309.01 | 2022-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $308.08 | 2024-2025 | Voquezna |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $245.74 | 2019-2025 | Ocaliva |
| Merck Sharp & Dohme LLC | $184.87 | 2019-2024 | Dificid |
| Daiichi Sankyo INC. | $147.35 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $127.05 | 2020-2022 | |
| Shionogi INC | $124.52 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $123.04 | 2019-2023 | Stelara, Remicade, Tremfya |
| Aimmune Therapeutics, INC. | $118.28 | 2024-2025 | Zenpep |
| Intuitive Surgical, INC. | $112.89 | 2019 | |
| Celltrion USA INC. | $106.95 | 2024-2025 | Vegzelma |
| Laborie Medical Technologies Corp. | $75.54 | 2023 | |
| Redhill Biopharma INC. | $71.01 | 2021-2022 | |
| Allergan, INC. | $61.98 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $55.58 | 2019-2021 | |
| Endo Pharmaceuticals INC. | $49.71 | 2019-2020 | |
| Alfasigma USA, INC. | $43.35 | 2020 | |
| Amgen INC. | $38.05 | 2023 | Amjevita, Avsola |
| Echosens North America, INC. | $34.45 | 2024 | Fibroscan |
| Mylan Institutional INC. | $25.09 | 2023 | |
| Lucid Diagnostics INC. | $19.16 | 2023 | |
| Capsovision, INC. | $18.64 | 2023 | Capsocam Plus |
| Shire North American Group INC | $18.40 | 2019 | |
| Organon LLC | $16.59 | 2023 | Hadlima, Renflexis |
| Ucb, INC. | $16.09 | 2019 | |
| Portola Pharmaceuticals, LLC | $14.69 | 2019 | |
| Novo Nordisk INC | $14.19 | 2025 | Wegovy |
| Sandoz INC. | $12.94 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Meister listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.